Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aeterna Zentaris Inc

Current price
2.11 USD +0.053 USD (+2.57%)
Last closed 2.09 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 10 100 230 USD
Yield for 12 month -44.12 %
21.11.2021 - 28.11.2021

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina. Address: 315 Sigma Drive, Summerville, SC, United States, 29486


WallStreet Target Price

15 USD

P/E ratio

Dividend Yield

4.8 %

Current Year

+5 640 000 USD

Last Year

+5 260 000 USD

Current Quarter

+3 000 USD

Last Quarter

+2 246 000 USD

Current Year

+5 483 000 USD

Last Year

+5 170 000 USD

Current Quarter

-8 000 USD

Last Quarter

+2 107 000 USD

Key Figures AEZS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -15 701 000 USD
Operating Margin TTM -151666.67 %
PE Ratio
Return On Assets TTM -18.03 %
PEG Ratio
Return On Equity TTM -61.74 %
Wall Street Target Price 15 USD
Revenue TTM 6 862 000 USD
Book Value 5.41 USD
Revenue Per Share TTM 1.41 USD
Dividend Share
Quarterly Revenue Growth YOY -99.8 %
Dividend Yield 4.8 %
Gross Profit TTM 5 170 000 USD
Earnings Share -4.81 USD
Diluted Eps TTM -4.81 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AEZS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AEZS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 4.8 %
Last Split Factor 1:25
Payout Ratio
Last Split Date 21.07.2022
Dividend Date

Stock Valuation AEZS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.159
Price Sales TTM 1.4719
Enterprise Value EBITDA 1.2669
Price Book MRQ 0.3844

Financials AEZS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AEZS

For 52 weeks

1.36 USD 4 USD
50 Day MA 1.84 USD
Shares Short Prior Month 46 753
200 Day MA 2.61 USD
Short Ratio 5.48
Shares Short 47 544
Short Percent 0.98 %